This month featured ESMO updates, breast cancer trial news, social media strategies for oncologists, and mastectomy body ...
Researchers assessed preoperative lesion area as a predictor of final defect size in periocular basosquamous carcinoma cases.
In patients with extensive-stage small cell lung cancer, adding tarlatamab to durvalumab maintenance therapy significantly ...
Perioperative apalutamide plus ADT and surgery lowered risk of recurrence or death by 62% in high-risk localized or locally advanced prostate cancer.
Sanjay Juneja, MD, a triple board-certified hematologist and medical oncologist known as @TheOncDoc, translates oncology fundamentals.
Updated findings from the OptimUM trials support the use of darovasertib plus crizotinib in the treatment of patients with ...
Pembrolizumab continues to demonstrate a disease-free and overall survival benefit for patients with clear cell renal ...
Combining the novel, highly selective HDAC inhibitor HBI-8000 with nivolumab significantly improves PFS in unresectable ...
Over the last 15 years, low-risk prostate cancer has become less common at diagnosis and is increasingly managed through active surveillance, according to research published in Ca ...
Combining adjuvant ribociclib with an NSAI improves long-term survival in HR-positive, HER2-negative early breast cancer over ...
Niraparib plus dostarlimab with definitive cisplatin plus radiotherapy improves some outcomes in patients with locally ...
In patients with muscle-invasive bladder cancer (MIBC), treatment with neoadjuvant durvalumab and enfortumab vedotin, with or ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results